Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quattroflow™ Introduces 5050 Series Quaternary Diaphragm Pumps

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Ideal for use in demanding biotech and pharmaceutical applications.

Quattroflow™ has announced the introduction of its 5050 Series Quaternary Diaphragm Pump to its family of biotech and pharmaceutical pumps.

This innovative pump system features compact dimensions, multi-directional connections and the ability to satisfy a wide variety of flow-rate requirements, which makes it ideal for use in demanding biotech and pharmaceutical applications.

The 5050 pump provides multi-option installation flexibility and a compact design. The unit is drainable and cleanable, and includes multi-directional pump-head connections and positioning.

The 5050 pump features a 225mm (8.86”) chamber diameter and 50mm (1-1/2”) flange porting.

The 5050 pump has a wide flow range from 50 to 5,000 L/hr (13 to 1,321 gph), with maximum pressure to 6 bar at 20°C (87 psi at 68°F). The complete flow range can be achieved with one drive, no further drive options needed.

The pump chamber is available in 316L stainless steel for multiple-use and polypropylene (PP) for single-use applications. The pump’s valves are constructed of EPDM, while the diaphragm is Santoprene® (EPDM/PP compound).

Quattroflow’s positive displacement pumps incorporate a four piston-diaphragm technology with no mechanical seals that is driven by an eccentric shaft and motor.

Quattroflow products primarily serve the biotech and pharmaceutical industries that require gentle displacement, reliability, product safety, purity and cleanability.

The 5050 pump can be found in multiple or single-use applications within cross-flow systems, chromatography devices and centrifuges.

Quattroflow is a leading brand from Almatec, which is part of Dover Corporation’s Pump Solutions Group (PSG®).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!